Amarin Corporation plc · NASDAQ:AMRN

Amarin — Investor Presentation (September 2008)

29 slides from Amarin's investor presentation, September 2008

  1. Slide 1: Corporate Presentation September 2008

    Corporate Presentation September 2008 NASDAQ: AMRN THE FUTURE IN MIND

  2. Slide 2: Safe Harbour

    Safe Harbour DISCLOSURE NOTICE:The information contained in this document is as of September 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking

  3. Slide 3: Corporate Focus

    Corporate Focus Amarin is a clinical-stage biopharmaceutical company with a lead program entering Phase 3 for hypertriglyceridemia. Amarin’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular

  4. Slide 4: Overview

    Overview y Company repositioned to pursue cardiovascular opportunities which leverage in-house lipid science expertise y Low risk lead program - AMR101 (ethyl-EPA) – Near term - entering Phase 3 – Proven safety and tolerability – extensive data from Amarin CNS studies – EPA efficacy established – Ep

  5. Slide 5: Corporate Strategy

    Corporate Strategy y Cardiovascular disease programs prioritised – FDA meeting paves way for Phase 3 hypertriglyceridemia program – Programs leverage Amarin’s leading lipid science expertise – Collaborate with large pharmaceutical companies to commercialise our products to physician populations in b

  6. Slide 6: Management Team

    Management Team Thomas Lynch 25 years management, finance, strategy Chairman and Chief Executive Officer Elan, Warner Chilcott, ICON Alan Cooke 16 years management, finance, strategy President & Chief Operating Officer Elan, KPMG Declan Doogan, MD 30 years development, management Head, Research & De

  7. Slide 7: Board of Directors

    Board of Directors Thomas Lynch 25 years management, finance, strategy Chairman & Chief Executive Officer Elan, Warner Chilcott, ICON Dr. William Mason Founded successful high technology biomedical companies Lead independent Director 20 years of neuroscience-focused medical research in Cambridge Dr.

  8. Slide 8: Cardiovascular Disease Programs

    Cardiovascular Disease Programs AMR101 for Hypertriglyceridemia entering Phase 3 AMR101 for other cardiovascular indications planning Follow on candidates preclinical 8

  9. Slide 9: Hypertriglyceridemia and Dyslipidemia Overview

    Hypertriglyceridemia and Dyslipidemia Overview • Hypertriglyceridemia a condition in which patients have high blood levels of triglycerides (TGs) • High TGs are associated with increased levels of heart disease, while very high TGs are associated with pancreatitis • Hypertriglyceridemia is a subset

  10. Slide 10: Prescription Omega-3s – multi $billion market

    Prescription Omega-3s – multi $billion market • First prescription Omega-3 launched in US in 2005 (Lovaza) – predicted to reach blockbuster status – current worldwide run rate of $700m, US year on year growth 60%+ • Broad use by physicians – Monotherapy, add-on and in combination with statins, niaci

  11. Slide 11: Japan EPA Lipid Intervention Study (JELIS)

    Japan EPA Lipid Intervention Study (JELIS) Yokoyama M. The Lancet 2006 18,645 Japanese men and women randomized to statin alone or statin + EPA (Epadel) and followed for 5 years 4 Cumulative Incidence of Major Control (statin) EPA (statin+Epadel) –19% (p=0.011) Coronary Events (%) 3 2 1 0 0 1 2 3 4

  12. Slide 12: AMR101 description

    AMR101 description • Prescription grade long chain Omega-3 - highly unsaturated fatty acid (20:5n-3) • Ultra-pure (97%) ethyl ester of eicosapentaenoic acid (ethyl-EPA) • Potential powerful natural protector against cardiovascular disease • Acts through vascular remodelling in managing endothelial d

  13. Slide 13: AMR101 for Hypertriglyceridemia

    AMR101 for Hypertriglyceridemia • Excellent safety and tolerability profile – Substantial body of data on AMR101 generated by Amarin to date – Over 900 patients (western population) have received AMR101 (>100 for year or more) • Phase 3 program to commence in 2009 – FDA meeting provides pathway • Ef

  14. Slide 14: Preclinical Programs in Cardiovascular

    Preclinical Programs in Cardiovascular • Follow on candidates in preclinical development – New lipid compounds – Leveraging Amarin’s expertise in lipid science and experience developing AMR101 – Offer significantly higher potency than current Omega-3s – Preclinical studies to be conducted in academi

  15. Slide 15: CNS Pipeline – Assets for Partnering

    CNS Pipeline – Assets for Partnering 15

  16. Slide 16: CNS Programs for Partnering

    CNS Programs for Partnering Pre-Clin Phase Phase Phase Candidate Indication Mechanism 1 2 3 AMR101 Huntington’s Mitochondrial Disease function Myasthenia mRNA AChE-R EN101 Gravis silencing Sublingual Parkinson’s Dopamine Apomorphine Disease agonist Nasal Epilepsy GABA-A Lorazepam seizures binding Pa

  17. Slide 17: Financial Review

    FINANCIAL REVIEW 17

  18. Slide 18: Consolidated Summary Income Statement

    Consolidated Summary Income Statement All amounts in US$000 Q2 2008 Q1 2008 FY 2007 Revenue - - - Operating expenses R&D 1,971 2,604 10,772 SGA 3,842 4,215 16,176 Share based compensation (non-cash) 936 1,010 5,001 Impairment of intangible assets - - 8,784 Total operating expenses (6,749) (7,829) (4

  19. Slide 19: Consolidated Balance Sheet

    Consolidated Balance Sheet All amounts in US$'000 30-Jun 2008 Property, plant and equipment 527 Intangible assets 19,916 Available for sale investment 11 Non-current assets 20,454 Income tax recoverable 1,256 Other current assets 1,500 Cash 26,340 Current assets 29,096 Total assets 49,550 Non-curren

  20. Slide 20: 2008 Milestones

    2008 Milestones 9 In-licensing - expansion of global IP for lipid platform 9 Completion of $30m first tranche of potential $60m financing 9 Addition of highly experienced Board members from top US funds 9 FDA meeting paves way for Phase 3 AMR101 in hypertriglyceridemia 9 External panel of cardiovasc

  21. Slide 21: Investment Highlight Summary

    Investment Highlight Summary • Company leveraging leading proprietary lipid science expertise to participate in multi-$billion prescription Omega-3 sector • AMR101 (ethyl-EPA) for Hypertriglyceridemia – Phase 3, low risk opportunity with significant revenue potential – Safety of AM101 established an

  22. Slide 22: Contacts

    Corporate Presentation September 2008 NASDAQ: AMRN Contacts: Amarin Corporation First Floor, Block 3, The Oval Ballsbridge, Dublin 4, Ireland THE FUTURE IN MIND Phone: +353 1 6699020 Email: investor.relations@amarincorp.com

  23. Slide 23: Supplemental Information on Assets for Partnering

    Supplemental Information on Assets for Partnering Amarin Business Development Email: bd@amarincorp.com THE FUTURE IN MIND

  24. Slide 24: AMR101 for Huntington’s Disease

    AMR101 for Huntington’s Disease y Two large Phase 3 trials completed in Q2 2007 y No difference versus placebo as 6 months y Positive data at 12 months: - Statistically significant (p=0.02), particularly in pre-specified genetic subgroup with CAG<44 (p=0.004) - Longer term benefit consistent with pr

  25. Slide 25: EN101 for Myasthenia Gravis

    EN101 for Myasthenia Gravis • EN101 is a selective AChE (R–isoform) mRNA inhibitor in development for myasthenia gravis (MG) • MG is a progressive and potentially fatal disease affecting 60,000 in US alone – Symptoms include weakness of muscles that control eye, facial expression, speech and swallow

  26. Slide 26: Sublingual Apomorphine for Parkinson’s Disease

    Sublingual Apomorphine for Parkinson’s Disease • 30% of Parkinson's patients have advanced disease • Characterized by frequent “off” periods of semi-paralysis • Use of existing apomorphine product for “off” periods restricted due to multiple, painful injections every day, often severe local reaction

  27. Slide 27: Nasal Lorazepam for Emergency Seizures

    Nasal Lorazepam for Emergency Seizures • Prolonged or repetitive seizures - emergency • 40,000 deaths in US per year • Treated primarily with IV lorazepam in hospital ER • Rectal diazepam gel is only approved out patient treatment Potential Nasal Spray • Nasal formulation provides ease of administra

  28. Slide 28: Targeted Lipid Transport Platform

    Targeted Lipid Transport Platform • Proprietary patent protected technology platform • Novel means of improving systemic bioavailability and/or transport to the brain • Chemically conjugating bioactive lipids with other lipids or existing drugs – Results in novel single chemical entities offering cl

  29. Slide 29: Supplemental Information on Assets for Partnering

    Supplemental Information on Assets for Partnering Amarin Business Development Email: bd@amarincorp.com THE FUTURE IN MIND

Amarin — Investor Presentation (September 2008) on 6ix